SATYANARAYANA B

Spearheaded the marketing operations of Ultra Laboratories, which is an upcoming leading pharma company in India. Developed, implemented go-to-market strategies and sales business operation plan in covered regions. Identified the right product mix to launch and manage product communications of Acute, Chronic and Infusion range portfolio. Accomplishments: Launched the division with a product basket of 33 SKU within a short time of 6 months. Crossed 1 Cr+ milestone within 8 months of launch.

Developed, implemented and measured the marketing strategies, tactical business plans for the products cater to anaesthesia and critical care portfolio. Accomplishments: Increased stakes in anaesthesia and critical care portfolio by launching inhalational anaesthetics Sevfurane, Iflurane, Plasvex and HumanIG brands worth of 10 Cr. Supervised promotional activities for therapy leaders Atrapure, Samvec, Cisatra and Rocpure brands.

Developed marketing strategies to increase the brand performance of Pilex worth of 46 Cr. Accomplishments: Developed and executed the patient awareness campaign through a digital tool for the brand Pilex. This campaign helped to reach 6000 target doctors and surpassed the 100% achievement in FY Feb'20.

Conducted market research, analysed the market trends and competition, Identified the treatment gaps in therapy, proposed go-to-market strategic ideas for the new brands launch. Initiated innovative brand campaigns, developed and executed customer centric tactical brand strategies by using multi-level marketing approach which resulted in brand building and maintaining product mix performance. Increased the brands noise level and visibility by conducting hospital CMEs, Symposiums and departmental meetings. Actively participated in national and regional level conferences through networking with KOLs, KBLs, medical societies and professional key advisories. Accomplishments: Built three major brands Micropenam (12 Cr), Microtaz (8.5 Cr) & Dolo IV (6.5 Cr) in a short span, which helped division to achieve budgets every year. Launch of brand extensions of Hopstin 3 MIU & 4 MIU led an incremental sale of 1 Cr. Generated 1 Cr sales by the launch of new brands ICUFOS and Microdox. Achieved 42 Cr sales from critical care portfolio by developing and implementing result-oriented marketing strategies, business driven sales plan. This was 70% contribution to the division of 60 Cr budget.

Key accountant, acted as a catalyst to drive, monitor, and execute implementation of marketing strategies across south II zone. Retained the major counters, existing KOLs, add-on potential new prescribers and KOLs from the key business counters like CMC, Apollo, HCG, NH etc hospitals to ensure brand building. Accomplishments: South II zone ensured to perform 110% sales achievement. Executed highest number of departmental CMEs, product demos, RTMs, Symposiums to train the PG's, Dept. Dr's and Paramedics, which resulted in well product mix sales for the focused brands Voluven, Volulyte, Kabimol, Fresofol and Freeflex.

Handled the pillar brand Anxit to achieve 24 Cr. Assisted in new brand launches Beta-Anxit, Ebast suspension and Ebast-M Kid and facilitated product training.

Assisted in brand launches, brand campaigns and designing of promotional inputs like visual aid, LBLs and brochures.

Achieved pool sales target and earned the product incentives. 1st rank reward in product knowledge during training programme.